Brain cancer vaccine targets survivin protein to boost immune attack
Disease control
Not yet recruiting
This phase II trial tests whether a personalized dendritic cell vaccine targeting the Survivin protein can improve survival in people with newly diagnosed glioblastoma, an aggressive brain cancer. Participants receive the vaccine alongside standard chemotherapy after surgery. The…
Phase: PHASE2 • Sponsor: Beijing Tricision Biotherapeutics Inc • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC